New Dual-Targeting CAR-T therapy enters human trials for bone marrow cancer

NCT ID NCT07073547

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This early-phase trial tests a new treatment called AZD0120 for adults with multiple myeloma, a type of blood cancer. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and CD19). The main goals are to check safety and find the right dose, while also looking at how well it works. About 40 participants will take part in this open-label study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Research Site
WITHDRAWN

Phoenix, Arizona, 85054, United States
Research Site
RECRUITING

Duarte, California, 91010, United States
Research Site
RECRUITING

Denver, Colorado, 80218, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Atlanta, Georgia, 30322, United States
Research Site
RECRUITING

Iowa City, Iowa, 52242, United States
Research Site
WITHDRAWN

Rochester, Minnesota, 55905, United States
Research Site
RECRUITING

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

New York, New York, 10016, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
WITHDRAWN

Dallas, Texas, 75235, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.